Structure Therapeutics (GPCR) Accumulated Expenses (2022 - 2026)

Structure Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 34.03% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $6.4 million, a 34.03% increase from a year earlier, with the FY2025 full-year figure at $46.5 million, up 538.45% from the prior year.
• Accumulated Expenses declined to $6.4 million in Q1 2026 per GPCR's latest filing, from $46.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $46.5 million in Q4 2025 and bottomed at $1.1 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $6.6 million (2022), against an average of $12.8 million.
• Across the five-year window, Accumulated Expenses surged 1247.99% in 2024 and sank 70.3% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $6.7 million in 2022, then surged by 175.3% to $18.6 million in 2023, then plunged by 60.72% to $7.3 million in 2024, then soared by 538.45% to $46.5 million in 2025, then plunged by 86.32% to $6.4 million in 2026.
• Per Business Quant, the three latest GPCR Accumulated Expenses figures stand at $6.4 million (Q1 2026), $46.5 million (Q4 2025), and $36.9 million (Q3 2025).